Elan And Biogen Idec Submit Supplemental Biologics License ...
Medical News Today (press release) - UK
The filing is based on the results of three randomized, double-blind, placebo-controlled, multi-center trials of TYSABRI assessing the safety
and efficacy ...

Elan and Biogen jump on Crohn's filing for Tysabri
Reuters - USA
NEW YORK (Reuters) - Elan Corp. and Biogen Idec on Friday said they
asked US regulators to approve use of their multiple sclerosis drug
Tysabri, ...

Biogen Idec, Elan rise after Tysabri application
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
In the US, Tysabri is currently approved to treat relapsing forms of
multiple sclerosis. In early trading, Biogen Idec BIIB gained 1.8% to $51.97, ...